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Table 1
Sex of Offspring of Cancer Survivors (Stratified by Type of Treatment Received) and of Sibling Controls
SEX OF OFFSPRING
STRATIFIED BY
SEX OF SUBJECTS
NO. OF OFFSPRING OF
SURVIVORS WHO RECEIVEDa,b
NO. OF
OFFSPRING
OF SIBLING
CONTROLSb
NO. OF OFFSPRING OF
SURVIVORS WHO RECEIVEDc
Potentially
Mutagenic
Therapy
Less- or
Nonmutagenic
Therapy
Potentially
Mutagenic
Therapy
Less- or
Nonmutagenic
Therapy
Male subjects:
Male offspring 100 344 1,022 137 529
Female offspring 94 340 1,021 141 522
Subtotal (sex ratio) 194 (1.06) 684 (1.01) 2,043 (1.00) 278 (0.97) 1,051 (1.01)
Female subjects:
Male offspring 98 513 1,278 140 794
Female offspring 116 498 1,223 165 731
Subtotal (sex ratio) 214 (0.84) 1,011 (1.03) 2,501 (1.04) 305 (0.85) 1,525 (1.09)
Total 408 1,695 4,544 583 2,576
a The sum of offspring of survivors treated with potentially mutagenic therapy and those treated with less- or
nonmutagenic therapy is slightly less than the total number of offspring of the survivors, because the site of radiotherapy,
in some patients, was not known.
b Data on offspring of subjects from original study (Byrne et al. 1998).
c Combined data (Hawkins 1991; Byrne et al. 1998).
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Genetic Disease in Offspring of Long-Term Survivors
of Childhood and Adolescent Cancer Treated with
Potentially Mutagenic Therapies
To the Editor:
With increasing survival to reproductive age among in-
dividuals treated during childhood or adolescence by
anticancer regimens that included mutagenic agents—
and, in many cases, with recovery of fertility—there is
concern that germ cells may carry mutations that could
lead to genetic disease in offspring. A large body of ev-
idence suggests that radiation and alkylating agents are
mutagenic toward germ cells (Witt and Bishop 1996).
However, numerous studies evaluating genetic disease
among offspring of individuals who previously received
therapy for cancer with radiation or chemotherapy have
not found evidence of significant increases in such ge-
netic disease in the offspring (Byrne et al. 1998).
Nevertheless, the following questions remain: What is
the upper confidence limit of the level of genetic disease
that might have been induced but remained undetected?
How can the information available be used in combi-
nation with future studies, with the goals of either de-
tecting genetic disease or further lowering this upper
confidence limit?
In the largest study of genetic disease among offspring
of cancer survivors (Byrne et al. 1998), 2,198 offspring
of 1,062 long-term survivors of childhood cancer and
4,544 offspring of 2,032 sibling controls were studied.
Most of the data were analyzed to compare the 2,198
offspring of the overall group of cancer survivors with
those of the sibling control group. However, only 235
of the 1,062 cancer survivors received “potentially mu-
tagenic therapy,” defined as either radiotherapy below
the diaphragm and above the knee or chemotherapy
with an alkylating agent. The 408 offspring of these 235
survivors constitute the group most likely to be at risk
for genetic disease, since the other 1,790 offspring were
born to parents who received treatment that would be
expected either to be nonmutagenic or to have a low
mutagenic potential. We thought it essential for proper
interpretation of the results of this study, as well as for
combining these data with the results of other studies,
to separately report all of the data on genetic disease in
the offspring, according to the mutagenic potential of
the therapy received by their parents, which was not
done in the original report (Byrne et al. 1998). Further-
1070 Letter to the Editor
Table 2
Genetic Disease among Offspring of Cancer Survivors Treated with Potentially Mutagenic
Therapy or with Less- or Nonmutagenic Therapy and among Controls, Stratified by Sex of
Parent Who Was a Subject
SEX OF SUBJECT
NO. OF OFFSPRING WITH GENETIC DISEASE/TOTAL OFFSPRING (%)
Offspring of Survivors
Treated with Potentially
Mutagenic Therapy
Offspring of Survivors
Treated with Less- or
Nonmutagenic Therapy
Offspring
of Sibling
Controls
Male 6/194 (3.1%) 17/684 (2.5%) 67/2,043 (3.3%)
Female 7/214 (3.3%) 44/1,011 (4.4%) 75/2,501 (3.0%)
Total 13/408 (3.2%) 61/1,695 (3.6%) 142/4,544 (3.1%)
NOTE.—Data on offspring of subjects from original study (Byrne et al. 1998).
more, since mechanisms of mutation induction differ by
sex—because different germ cells are at risk—we have
also stratified the data by the sex of the exposed survivor,
which was not done consistently in the original study.
Table 1 presents the numbers of survivors and their
offspring, stratified as described above. There were no
significant differences between the male-to-female sex
ratios among the offspring of the group treated with
potentially mutagenic therapy and any of the control
groups (the survivors treated with nonmutagenic ther-
apy, the siblings of the survivors, or the combination of
these two groups). However, when these data are com-
bined with the second largest study of offspring of sur-
vivors of childhood cancer, which involved 161 offspring
of survivors who had received potentially mutagenic
therapy (Hawkins 1991), the male-to-female sex ratio
among offspring of female survivors who had received
potentially mutagenic therapy (0.85) was significantly
lower than that for survivors exposed to nonmutagenic
therapy (1.09) and, in further support of the result, was
lower than that for the general population (1.06) (both
, two-tailed x2 test). Although this shift is in thePp .05
expected direction for induction of mutations, since sex-
linked lethal mutations on the X chromosomes would
selectively reduce the number of male offspring, the sta-
tistical significance of the result is marginal; future stud-
ies are needed to confirm or refute this observation.
Analysis of the incidence of all genetic disease among
the offspring (table 2) showed no significant difference
between the survivors who had received potentially mu-
tagenic therapy and any of the control groups for male
parents, female parents, or both sexes combined (P 1
). The frequency of genetic disease among offspring of.4
women treated with nonmutagenic therapy was mar-
ginally higher ( , two-tailed x2 test) than thatPp .045
among the offspring of sibling controls. Although the
marginal statistical significance may be a result of
chance, possible biological explanations for this unex-
pected finding are that some of the nonalkylating agents
may be mutagenic or may cause uterine damage, or the
higher frequency of uterine anomalies in girls with
Wilms tumor (Nicholson et al. 1996) may result in de-
formations that mimic genetically caused birth defects.
The data in table 2 were used to determine the min-
imum percentage increase in incidence of genetic disease
among the offspring of survivors treated with potentially
mutagenic therapy that, if present, could have been de-
tected with 95% confidence (one-tailed test for com-
parison of two proportions), because these treatments
produce mutations in many other systems), with a power
of 80% (Fleiss 1991). This increase was 85% when the
control group comprised only the offspring of the sib-
lings and 82% when the control group comprised the
offspring of siblings and those exposed to nonmutagenic
treatment. Note that these incidences are higher than the
40% increase reported in the original study, because we
limited the group at risk to the offspring of survivors
who had received potentially mutagenic therapy. Fur-
thermore, when these data are combined with those of
the Hawkins study (Hawkins 1991), there is still no
evidence of an increase in genetic disease in the offspring
of survivors treated with potentially mutagenic therapy,
but the upper limit of the possible increase in genetic
disease that would have remained undetected is slightly
reduced, to 76%.
In table 3, the specific types of genetic disease are
stratified according to the type of treatment received.
There were no significant differences in the frequencies
of the individual types of genetic disease between the
offspring of survivors treated with potentially mutagenic
therapy and those of any of the control groups ( ),P 1 .3
whether the data were analyzed for the offspring of male
and female survivors individually (see footnotes, table
3) or after grouping the offspring of male and female
survivors.
Thus, this reexamination of the original report (Byrne
et al. 1998) failed to detect any significant induction of
genetic disease in offspring of survivors treated with po-
tentially mutagenic therapy for childhood cancer, but it
raised the upper limit on the percentage increase that
can be ruled out. Further studies must be pursued to
determine whether there are low levels of induced genetic
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Table 3
Genetic Disease among Offspring of Cancer Survivors Treated with Potentially Mutagenic Therapy, or with
Less- or Nonmutagenic Therapy and among Control Subjects, by Type of Genetic Disease
TYPE OF GENETIC DISEASE
NO. (%) OF OFFSPRING WITH GENETIC DISEASE
Offspring of Survivors
Treated with Potentially
Mutagenic Therapy
Offspring of Survivors
Treated with Less- or
Nonmutagenic Therapy
Offspring of Control
Subjects
Cytogenetic syndrome 0 (0.0%) 4 (.2%)a 6 (.1%)
Single-gene disorder 1 (.2%)b 13 (.8%)c 10 (.2%)
Simple malformation only 12 (2.9%)d 44 (2.6%)e 127 (2.8%)
Total 13/408 (3.2%) 61/1,695 (3.6%) 142/4,544 (3.1%)f
NOTE.—Data on offspring of subjects from original study (Byrne et al. 1998).
a All cases (one in the offspring of a male survivor and three in offspring of female survivors) were sporadic.
b The single-gene disorder occurred in the offspring of a female subject and was familial.
c All but one of these cases (in an offspring of a male survivor) were familial.
d Six of the simple malformations (all sporadic) occurred in the offspring of male subjects, and six (five of
which were sporadic) occurred in the offspring of female subjects.
e Twelve cases (11 of which were sporadic) occurred in offspring of male subjects and 32 (27 of which were
sporadic) in offspring of female subjects.
f One of the offspring had both a single-gene (familial) disorder and simple malformations.
disease among offspring of patients treated with poten-
tially mutagenic anticancer agents and, if no increases
are found, to provide data for meta-analyses to further
reduce the level of increase in genetic disease that can
be excluded.
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